Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from cactaceae
Reexamination Certificate
2001-01-22
2002-09-10
Lankford, Jr., Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from cactaceae
C424S400000, C424S502000, C424S725000, C514S946000, C514S947000
Reexamination Certificate
active
06447820
ABSTRACT:
BACKGROUND OF INVENTION
If an organ receives a physical trauma, such as an injury, surgery, a burn or an electric shock, or experiences inflammation as a result of a pathogenic cause, one of the inevitable consequences of the healing and inflammatory processes, which follow, is the formation of scar tissue. Scar tissue is formed as a result of the formation of a fibrin-platelet network following physical trauma or pathogenic inflammation, and the subsequent rebuilding and replacement of this network by granulation tissue.
The complex and typically highly irregular structure of the fibrin-platelet network, formed at an early stage after the trauma or as a result of inflammation, is of key importance in the fate of any wound healing process. Any physical structure, particularly filaments and membranes, whether diffusely or distinctly outlined, acts as a guide for the invading granulation tissue. This newly formed tissue is, in accordance with the mechanism described above, eventually rebuilt as scar tissue, organized is fibrous strands or membranes. The invading granulation tissue cells can practically never fully substitute for the original cells and, as a result, the tissue is never regenerated, but merely repaired. This is true for both the skin and for mucosal membranes, including those lining the body cavities, as well as other structures including muscles, tendons and nerves. Moreover, the scar tissue so formed may, in time, contract and remain contracted, deforming and disorganizing the injured area.
The proliferation and invasion of fibrin threads by even a few granulation tissue cells (including angiogenic cells) is usually sufficient to induce the formation of adhesions. The direction, density and organization of the individual fibrin threads in the fibrin-platelet network of the clot provides information, and determines the track to be taken by the invading granulation tissue cells, as well as by specific cells such as Schwann cells. Extracellular fibrin may deposit, stick to and establish abnormal bridges between adjacent structures. Thus, the structure of the fibrin-platelet network is of key importance in guiding the invading granulation tissue and thus in the formation of scar tissue.
Notwithstanding considerable literature on modalities of prevention of scar formation and removal of formed scar which have included the use of pressure dressings, splints, the application of silicone gel, steroid injections, protective devices, stretching devices, blood byproducts, protein solutions, gauzes, bandages, tapes and radiotherapy but all have had limited success and at times unwanted side effects.
Several patents have been granted for compositions claiming to prevent or treat human tissue scar formation, use of cactus and phellodendri. The following is a summary of some patents relevant to the invention described here.
European Patent Application EP 0 051 354 describes a polymeric substrate coated with the polysaccharide chitosan, to which is appended the antithrombotic agent heparin.
The U.S. Pat. No. 5,116,824 describes a composite material comprising an N-acylchitosan and collagen, which is suitable for, wound dressings. Heparin may be incorporated as an antithrombotic agent.
The U.S. Pat. No. 6,159,494 to Widgerow, et al., describes a method whereby postoperative scars are treated by a method of applying a microporous paper tape to the scar running along the length of the scar. A contact medium is applied to the exposed surface of the tape and penetrates to the skin. The contact medium comprises an expressed gel from the plant
Bulbine frutescens
and may contain asiaticoside and panthenol.
The U.S. Pat. No. 6,120,520 to Saadat, et al., is for an apparatus and methods for stimulating revascularization and tissue growth having a directable end region carrying a tissue piercing end effector. The apparatus optionally includes electrodes for depositing RF energy to form a controlled degree of scar tissue formation, means for delivering a controlled amount of a bioactive agent at the treatment site, or both.
The U.S. Pat. No. 6,127,348 to Roufa, et al., comprises the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions.
The U.S. Pat. No. 6,110,459 to Mickle, et al., is for a method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts.
The U.S. Pat. No. 6,093,388 to Fergusons is for treating fibrotic disorders using mannose-6-phosphate composition.
The U.S. Patent to Sawyer, et al., is for the inhibitors, obtainable from tissue or secretions of leeches typically of the order Rhynchobdellida to include the treatment of Crohn's disease, tumor implantation, atherosclerosis, thrombotic microangiophathy, fibrous growths of the skin, acne, scar formation, membranous glomerulonephrits, cataracts, or infection with microfilarial nematodes.
The U.S. Pat. No. 5,994,325 to Roufa, et al., relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer.
The U.S. Pat. No. 5,981,606 to Martin pertains to invention of therapeutic TGF-beta-wound healing compositions for reducing the formation of scar tissue and increasing the proliferation and resuscitation rate of mammalian cells using pyruvate, an antioxidant and a mixture of saturated and unsaturated fatty acids and TGF-beta (GF) to form TGF-beta-wound healing compositions (ILA−D+GF). This invention also pertains to methods for preparing and using the TGF-beta-wound healing compositions.
The U.S. Pat. No. 5,919,476 to Fischer, et al., is for a bandage in the form of a reinforced silicone gel sheet for the treatment of scar tissue.
The U.S. Pat. No. 5,902,609 to Lee is for an invention that pertains to a composition for controlling wound scar production containing a calcium antagonist and a protein synthesis inhibitor.
The U.S. Patent to Fabo U.S. Pat. No. 5,891,076 is for a hypertrophic scar dressing that includes silicone-gel on that side of the dressing, which lies against the user's skin when worn.
The U.S. Pat. No. 5,885,982 to Dolynchuk, et al., is for a method of treating or preventing hypertrophic scar tissue in human skin comprising applying topically an effective amount of a non-toxic amine compound that is a transglutaminase inhibitor having a free amino group is disclosed. The amine compound that is a transglutaminase inhibitor is also selective for inhibiting Type III collagen peptide cross-linking.
The U.S. Pat. No. 5,885,581 to Massand is for a dermatological composition for use in improving the appearance of scars comprising 20-30 parts by weight of polyethylene glycol 200, 0.005-0.03 parts by weight of preservative, 0.05-0.2 parts by weight of sorbic acid, 0.5-2 parts by weight of allantoin, 1-3 parts by weight of xanthan gum, 5-15 parts by weight of fluid onion extract (Extract Allium Cepa), dermatologically acceptable aqueous carrier 55-65 parts by weight.
The U.S. Pat. No. 5,789,445 to Schweiger is for a topical application of benzoyl perioxide to regions of tissue scarring of a composition comprising several ingredients commonly used in cosmetic products for reduction and a softening of scar tissue.
The U.S. Pat. No. 5,736,508 to McMichael is for methods to eliminate or reduce the appearance of scar tissue by administration of streptolysin O.
The U.S. Pat. No. 5,731,298 to Reinmuller is for a pharmaceutical composition for non-topical wound, scar and keloid treatment is described which contains cross-linked glycosaminoglycans and conventional pharmaceutical auxiliary and/or carrier substances. The pharmaceutical composition i
Lankford , Jr. Leon B.
Srivastava Kailash C.
Welsh & Katz Ltd.
LandOfFree
Pharmaceutical composition for the prevention and treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for the prevention and treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for the prevention and treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2829849